Christa Noehammer,
Senior Scientist,
Austrian Institute of Technology
Christa Noehammer currently works as Senior Scientist at the Austrian Institute of Technology where she has been heading the Molecular Medicine research unit for several years. Holding a master degree in Microbiology and a PhD in Biochemistry she has been working in the microarray field since 1999 being involved in the design, production and data analysis of various microarray types thereby mainly focusing on minimally invasive biomarker discovery for cancer diagnostics. The last couple of years Dr. Noehammer has been very much involved in the setup of sampling - and biomarker isolation protocols as well as high throughput biomarker technologies for saliva diagnostics. Most recently she also started to work on saliva- and serum-derived exosomes aiming among others for the discovery of exosomal epigenetic biomarkers for early diagnosis of type 2 diabetes.
Saliva, Exosomes and Type 2 Diabetes Diagnostics
Thursday, 31 October 2019 at 08:30
Add to Calendar ▼2019-10-31 08:30:002019-10-31 09:30:00Europe/LondonSaliva, Exosomes and Type 2 Diabetes DiagnosticsCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Saliva is a readily and even within short time intervals repeatedly available body fluid, which can be obtained via non-invasive, painless collection. In addition, saliva represents a basically unlimited sample matrix and further offers the advantage of not requiring any special skills for collection. Saliva contains a broad range of relevant molecule classes, such as DNA, messenger RNA, micro RNA, lipids, proteins and antibodies, which all can be used as potential disease/health biomarkers. Along these lines Saliva diagnostics is an emerging field of molecular diagnostics, not least because scientific findings increasingly show that measuring and quantifying salivary biomolecules can be used not only to detect local diseases of mouth and throat but also to diagnose systemic diseases. Due to these opportunities and advantages a recent special interest of the Molecular Diagnostics research group at the AIT Austrian Institute of Technology is to evaluate saliva for its suitability for circulating biomarker-based diagnostics. Along these lines we will show proof of concept studies for autoantibody- and DNA-methylation based salivary diagnostics and report on the evaluation of different commercially available strategies for isolation of exosomes from human serum and saliva. We will further present data from comparative profiling studies in salivary - and serum-derived exosomes including targeted protein-, genome-wide microRNA – as well as DNA-methylation profiling. Last but not least we will report on results of a research project where we are looking for salivary and plasma exosome-derived epigenetic biomarkers for early type 2 diabetes diagnosis.
Add to Calendar ▼2019-10-30 00:00:002019-11-01 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-31 08:30:002019-10-31 09:30:00Europe/LondonSaliva, Exosomes and Type 2 Diabetes DiagnosticsCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
